Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.

about

Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.

Item

http://www.wikidata.org/entity/Q47672873

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Loss of BRCA1-associated prote ...... ant mesothelioma in effusions.

@en

Loss of BRCA1-associated protein 1

@nl

type

Item

label

Loss of BRCA1-associated prote ...... ant mesothelioma in effusions.

@en

Loss of BRCA1-associated protein 1

@nl

prefLabel

Loss of BRCA1-associated prote ...... ant mesothelioma in effusions.

@en

Loss of BRCA1-associated protein 1

@nl

P1476

Loss of BRCA1-associated prote ...... ant mesothelioma in effusions.

@en

P2093

Emma Rullo

http://www.w3.org/2001/XMLSchema#string

Florina Anca Oprescu

http://www.w3.org/2001/XMLSchema#string

P2860

High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology

Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.

The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment

What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.

P304

9-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DC.23837

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ilaria Cozzi

V Ascoli

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28994508

http://www.w3.org/2001/XMLSchema#string